Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.
Approval Alert | Three-Month Leuprolide Mesylate Formulation in Advanced Prostate Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pembrolizumab/Enfortumab Vedotin in Muscle Invasive Bladder Cancer
2
Fertility-Sparing Surgery May Be Safe Despite Recurrence in Cervical Cancer
3
Subcutaneous Mosunetuzumab Earns EU Approval in R/R Follicular Lymphoma
4
Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors
5
